Please login to the form below

Not currently logged in
Email:
Password:

Savient

This page shows the latest Savient news and features for those working in and with pharma, biotech and healthcare.

AZ moves a step closer to gout drug approval in US

AZ moves a step closer to gout drug approval in US

Another recent entrant into the market - Savient Pharmaceuticals - was unable to make headway with its Krystexxa (pegloticase) therapy and was forced to file for bankruptcy in 2013.

Latest news

  • AZ files gout drug lesinurad in Europe AZ files gout drug lesinurad in Europe

    Another recent entrant into the gout market - Savient Pharmaceuticals - was forced to file for bankruptcy in 2013 after poor sales of its gout therapy Krystexxa (pegloticase).

  • Phase III data back AZ's gout drug Phase III data back AZ's gout drug

    On the other hand, another recent entrant into the market - Savient Pharmaceuticals - was forced to file for bankruptcy last year on lacklustre sales of its gout therapy Krystexxa (pegloticase).

  • Good news for AZ on gout candidate lesinurad Good news for AZ on gout candidate lesinurad

    Another company with high expectations - Savient Pharma - was forced to file for bankruptcy protection in October after sales of its gout treatment Krystexxa (pegloticase) remained stubbornly low despite being launched in

  • Savient faces bankruptcy after Krystexxa sales disappoint Savient faces bankruptcy after Krystexxa sales disappoint

    Savient faces bankruptcy after Krystexxa sales disappoint. Agrees sale of assets including the gout drug. ... According to Reuters, Savient listed total assets of about $74m and liabilities of $260m as of June 30.

  • Novartis and Savient face NICE rejections Novartis and Savient face NICE rejections

    Novartis and Savient face NICE rejections. Jakavi and Krystexxa turned down for NHS use in England and Wales. ... On the same day that drugs for blood clot and diabetes were recommended for NHS use in England and Wales, healthcare authorities rejected

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest appointments

  • Basilea appoints commercial head Basilea appoints commercial head

    He joins from Savient Pharmacueticals where he served as president of the company's' European operations. ... It's at Bristol-Myers Squibb (BMS) where Veitch has spent most of his career, however, serving at the company from 1996 to 2011 when he joined

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics